The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy
NCT ID: NCT06282809
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2024-12-10
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The type of design is exploratory and is considered interventional. Following histotripsy, subjects will undergo imaging ≤36-hours post-index procedure. Additionally, subjects will be followed at 7-day, 14-day, 30-day, 60-day, 120-day, and 180-day timepoints.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HistoSonics System
HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy
Histotripsy is a non-thermal, mechanical process of focused ultrasound used to mechanically destroy targeted soft tissue.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy
Histotripsy is a non-thermal, mechanical process of focused ultrasound used to mechanically destroy targeted soft tissue.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
3. Subject is diagnosed with unresectable pancreatic adenocarcinoma (locally advanced \[Stage 3\] or oligometastatic disease \[Stage 4\]) confirmed via CT or MR imaging ≤14 days prior to the planned index procedure.
NOTE: If Stage 4 disease, there must be ≤5 metastatic tumors, the tumors must be located only in the liver and/or lung, and the metastatic tumors must be stable.
4. Subject is not a surgical candidate and has received chemotherapy ≥8 weeks.
5. Subject can tolerate general anesthesia.
6. Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-1 at baseline.
7. Subject meets the following criteria ≤14 days prior to the planned index procedure date:
* Hemoglobin ≥ 9 g/dL,
* Neutrophil count \>1.0 x 10\^9/L,
* Platelet \>50 x 10\^9/L,
* Total bilirubin ≤2.5x Institutional Upper Limit of Normal (IULN),
* Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5x IULN,
* International Normalized Ratio (INR) value \<1.5,
* Serum creatinine \<2.0mg/dL or an estimated glomerular filtration rate (eGFR) ≥45mL/min.
8. The targeted pancreatic tumor is ≥2 cm in longest diameter.
9. The planned histotripsy treatment volume is ≥1.0 cm from any portion of the duodenum, small intestine, stomach, or colon as visualized on ultrasound, and CT, or MR imaging.
10. Subject has an adequate acoustic window to visualize targeted tumor using the HistoSonics Edison System.
11. Subject will undergo histotripsy treatment of only one (1) tumor during the index procedure, regardless of how many tumors are present in the pancreas.
Exclusion Criteria
2. Subject has had prior pancreatic, bilioenteric, or gastric surgery.
3. Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.
4. Subject has an uncorrectable coagulopathy.
5. Subject has a life expectancy of less than six (6) months.
6. Subject has a biliary or pancreatic stent and/or percutaneous biliary tube that encompasses the planned histotripsy treatment volume.
7. Subject has metastases to organs other than the liver and/or lung (e.g., bone, brain, peritoneum).
8. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
9. Subject has an active duodenal or gastric ulcer requiring medical management.
10. Subject is undergoing active chemotherapy for any cancer ≤7 days prior to planned index procedure date.\*
11. Subject is undergoing active immunotherapy or targeted therapies ≤30 days prior to planned index procedure date.
12. Subject's targeted tumor has had prior locoregional therapy (e.g., ablation, embolization, or radiation).
13. Subject has a planned cancer treatment (e.g., pancreatic surgery, targeted therapy, immunotherapy) exclusive of chemotherapy, ≤30 days post index procedure.
14. Subject has planned chemotherapy ≤14 days post index procedure.\*
15. Subject has not recovered (CTCAE grade 2 or better) from chemotherapy or immunotherapy related toxicities (exclusive of alopecia, neuropathy, and exocrine insufficiency).
16. In the investigator's opinion, histotripsy is not a treatment option for the subject.
17. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
18. Subject's tumor is not treatable by the System's working ranges (refer to User Guide).
(\*) Subject must not be off chemotherapy \>21 days in total.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HistoSonics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Santiago Sanchez Cabús
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSP3325
Identifier Type: -
Identifier Source: org_study_id